Altermune Technologies LLC: Innovating novel therapeutics to combat resistant pathogens globally.
Altermune Technologies LLC was founded with the mission to develop novel therapeutics aimed at combating resistant pathogens such as MRSA, C. difficile, pseudomonas, and pandemic influenza. The company leverages a team of in-house scientists and a broad network of partnerships, including collaborative research arrangements with universities in the USA and Europe, as well as corporate relationships with companies specializing in oligonucleotide synthesis and aptamer selection. Their market focus is on addressing global health challenges posed by antibiotic-resistant bacteria and viral infections.
Notable affiliated individuals include a team of experienced scientists and researchers, though specific names are not provided. Altermune Technologies has established significant collaborations with academic institutions and industry partners, enhancing its research capabilities and innovation potential. The company's impact lies in its contribution to the development of advanced therapeutics that target some of the most challenging and resistant pathogens, aiming to improve global health outcomes.
Altermune Technologies' most recent funding round was for $7M (USD) in September 2011.
As of Sep 22, 2011, Altermune Technologies has disclosed funding of $7M (USD).

Altesa
altesabio.com

ArrePath
arrepath.com

Endolytix

Atterx BioTherapeutics
atterx.com
Chaperone Technologies

TAXIS Pharmaceuticals
taxispharma.com

X-Biotix Therapeutics
x-biotixrx.com

BLC USA
blcusalp.com

Armata Pharmaceuticals
armatapharma.com

Prokaryotics
prokaryotics.com
ImmunArtes

SciBac
scibac.com

PhagePro
phageproinc.com

Anti-Microbial Solutions

Antibiotic Adjuvant
a-adjuvant.com

Flightpath Biosciences
flightpath.bio

Bioharmony Therapeutics

Microbion
microbioncorp.com

AltPep
altpep.com

ExoLytics
exolytics.com